Standard BioTools
LAB
Standard BioTools (LAB) news
Recent news
Standard BioTools: withdrawing FY2026 revenue outlook given pending merger with TreeLine Biosciences
AInvest Wire · Aug 5, 2026Standard Biotools: Continued cost discipline drove 84% year-over-year improvement in adj EBITDA for Q2
Standard BioTools Inc. (NASDAQ: LAB) reported a 84% year-over-year improvement in adjusted EBITDA for the second quarter of 2025, driven by continued cost discipline and operational efficiency initiatives. The company’s adjusted EBITDA loss narrowed to $16.1 million in Q2 2025, compared to a $17.4…
AInvest Wire · Aug 5, 2026Standard BioTools - merger with TreeLine Biosciences expected to close before year-end 2026
AInvest Wire · Aug 5, 2026Standard Biotools - receives about $30 mln in cash from Illumina for waiver and release of obligations - SEC filing
AInvest Wire · Jul 28, 2026Standard Biotools-TreeLine deal seen closing by end of 2026
AInvest Wire · Jul 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.